메뉴 건너뛰기




Volumn 144, Issue , 2014, Pages

Role of tumour angiogenesis in haematological malignancies

Author keywords

Angiogenesis; Leukaemia; Myeloma; Vascular endothelial growth factor

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BORTEZOMIB; CD135 ANTIGEN; CEDIRANIB; FIBROBLAST GROWTH FACTOR 2; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; MIDOSTAURIN; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEASOME; SEMAXANIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; THALIDOMIDE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; PROTEASOME INHIBITOR; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

EID: 84962568419     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.14050     Document Type: Review
Times cited : (35)

References (103)
  • 1
    • 0028929803 scopus 로고
    • Angiogenesis in cancer, vascular, rheumatoid and other disease
    • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
    • (1995) Nat Med , vol.1 , pp. 27-31
    • Folkman, J.1
  • 2
    • 0031059348 scopus 로고    scopus 로고
    • Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
    • Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-21.
    • (1997) Am J Pathol , vol.150 , pp. 815-821
    • Perez-Atayde, A.R.1    Sallan, S.E.2    Tedrow, U.3    Connors, S.4    Allred, E.5    Folkman, J.6
  • 3
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-6.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 4
    • 0035160312 scopus 로고    scopus 로고
    • Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    • Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-201.
    • (2001) Nat Med , vol.7 , pp. 1194-1201
    • Lyden, D.1    Hattori, K.2    Dias, S.3    Costa, C.4    Blaikie, P.5    Butros, L.6
  • 5
    • 0036831559 scopus 로고    scopus 로고
    • Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
    • Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002;2:826-35.
    • (2002) Nat Rev Cancer , vol.2 , pp. 826-835
    • Rafii, S.1    Lyden, D.2    Benezra, R.3    Hattori, K.4    Heissig, B.5
  • 6
    • 20144386931 scopus 로고    scopus 로고
    • Contribution of bone marrow-derived endothelial cells to human tumor vasculature
    • Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261-2.
    • (2005) Nat Med. , vol.11 , pp. 261-262
    • Peters, B.A.1    Diaz, L.A.2    Polyak, K.3    Meszler, L.4    Romans, K.5    Guinan, E.C.6
  • 7
    • 0026485002 scopus 로고
    • Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
    • Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-5.
    • (1992) Nature , vol.359 , pp. 843-845
    • Shweiki, D.1    Itin, A.2    Soffer, D.3    Keshet, E.4
  • 8
    • 0034979159 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
    • Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol. 2001;280:C1367-74.
    • (2001) Am J Physiol Cell Physiol , vol.280 , pp. C1367-C1374
    • Dor, Y.1    Porat, R.2    Keshet, E.3
  • 9
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76.
    • (2003) Nat Med , vol.9 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 10
    • 0035793623 scopus 로고    scopus 로고
    • Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants
    • Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276:3222-30.
    • (2001) J Biol Chem. , vol.276 , pp. 3222-3230
    • Gille, H.1    Kowalski, J.2    Li, B.3    LeCouter, J.4    Moffat, B.5    Zioncheck, T.F.6
  • 11
    • 0035821293 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells
    • Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193:1005-14.
    • (2001) J Exp Med , vol.193 , pp. 1005-1014
    • Hattori, K.1    Dias, S.2    Heissig, B.3    Hackett, N.R.4    Lyden, D.5    Tateno, M.6
  • 12
    • 0033083962 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
    • Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-33.
    • (1999) Cancer Res , vol.59 , pp. 728-733
    • Bellamy, W.T.1    Richter, L.2    Frutiger, Y.3    Grogan, T.M.4
  • 13
    • 0037441869 scopus 로고    scopus 로고
    • Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor
    • Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101:1316-23.
    • (2003) Blood , vol.101 , pp. 1316-1323
    • Casella, I.1    Feccia, T.2    Chelucci, C.3    Samoggia, P.4    Castelli, G.5    Guerriero, R.6
  • 14
    • 0027197245 scopus 로고
    • Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
    • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-4.
    • (1993) Nature , vol.362 , pp. 841-844
    • Kim, K.J.1    Li, B.2    Winer, J.3    Armanini, M.4    Gillett, N.5    Phillips, H.S.6
  • 15
    • 77954600750 scopus 로고    scopus 로고
    • Clinical trials with anti-angiogenic agents in hematological malignancies
    • Medinger M, Mross K. Clinical trials with anti-angiogenic agents in hematological malignancies. J Angiogenes Res. 2010;2:10.
    • (2010) J Angiogenes Res , vol.2 , pp. 10
    • Medinger, M.1    Mross, K.2
  • 16
    • 77953520737 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies
    • Medinger M, Fischer N, Tzankov A. Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol. 2010;2010:729725.
    • (2010) J Oncol , vol.2010 , pp. 729725
    • Medinger, M.1    Fischer, N.2    Tzankov, A.3
  • 17
    • 4544267031 scopus 로고    scopus 로고
    • The role of angiogenesis in the biology and therapy of myelodysplastic syndromes
    • Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep. 2004;3:184-91.
    • (2004) Curr Hematol Rep , vol.3 , pp. 184-191
    • Aguayo, A.1
  • 18
    • 67649982789 scopus 로고    scopus 로고
    • Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: Correlation with clinical parameters and JAK2-V617F mutational status
    • Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009;146:150-7.
    • (2009) Br J Haematol , vol.146 , pp. 150-157
    • Medinger, M.1    Skoda, R.2    Gratwohl, A.3    Theocharides, A.4    Buser, A.5    Heim, D.6
  • 19
    • 0034655595 scopus 로고    scopus 로고
    • Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
    • Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-44.
    • (2000) Blood , vol.95 , pp. 2637-2644
    • Padro, T.1    Ruiz, S.2    Bieker, R.3    Burger, H.4    Steins, M.5    Kienast, J.6
  • 23
    • 20044371963 scopus 로고    scopus 로고
    • Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: Expression of angiopoietin-2 represents an independent prognostic factor for overall survival
    • Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol. 2005;23:1109-17.
    • (2005) J Clin Oncol , vol.23 , pp. 1109-1117
    • Loges, S.1    Heil, G.2    Bruweleit, M.3    Schoder, V.4    Butzal, M.5    Fischer, U.6
  • 24
    • 0033134764 scopus 로고    scopus 로고
    • Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase2 secretion parallel progression of human multiple myeloma
    • Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-73.
    • (1999) Blood , vol.93 , pp. 3064-3073
    • Vacca, A.1    Ribatti, D.2    Presta, M.3    Minischetti, M.4    Iurlaro, M.5    Ria, R.6
  • 25
    • 0035874498 scopus 로고    scopus 로고
    • Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner
    • Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001;97:3075-85.
    • (2001) Blood , vol.97 , pp. 3075-3085
    • Majka, M.1    Janowska-Wieczorek, A.2    Ratajczak, J.3    Ehrenman, K.4    Pietrzkowski, Z.5    Kowalska, M.A.6
  • 26
    • 84455193267 scopus 로고    scopus 로고
    • Endothelio-hematopoietic relationship: Getting closer to the beginnings
    • Gordon-Keylock S, Medvinsky A. Endothelio-hematopoietic relationship: getting closer to the beginnings. BMC Biol. 2011;9:88.
    • (2011) BMC Biol , vol.9 , pp. 88
    • Gordon-Keylock, S.1    Medvinsky, A.2
  • 27
    • 24044441296 scopus 로고    scopus 로고
    • Evidence for the hemangioblast
    • Park C, Ma YD, Choi K. Evidence for the hemangioblast. Exp Hematol. 2005;33:965-70.
    • (2005) Exp Hematol , vol.33 , pp. 965-970
    • Park, C.1    Ma, Y.D.2    Choi, K.3
  • 28
    • 0037182861 scopus 로고    scopus 로고
    • VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    • Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-8.
    • (2002) Nature , vol.417 , pp. 954-958
    • Gerber, H.P.1    Malik, A.K.2    Solar, G.P.3    Sherman, D.4    Liang, X.H.5    Meng, G.6
  • 31
    • 0033861874 scopus 로고    scopus 로고
    • Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
    • Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106:511-21.
    • (2000) J Clin Invest , vol.106 , pp. 511-521
    • Dias, S.1    Hattori, K.2    Zhu, Z.3
  • 32
    • 0036530301 scopus 로고    scopus 로고
    • VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition
    • Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2002;99:2532-40.
    • (2002) Blood , vol.99 , pp. 2532-2540
    • Dias, S.1    Shmelkov, S.V.2    Lam, G.3    Rafii, S.4
  • 33
    • 33947642080 scopus 로고    scopus 로고
    • Autocrine VEGF loops, signaling pathways, and acute leukemia regulation
    • Fragoso R, Elias AP, Dias S. Autocrine VEGF loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma. 2007;48:481-8.
    • (2007) Leuk Lymphoma , vol.48 , pp. 481-488
    • Fragoso, R.1    Elias, A.P.2    Dias, S.3
  • 34
    • 2342486598 scopus 로고    scopus 로고
    • Internal and external autocrine VEGF/ KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways
    • Santos SC, Dias S. Internal and external autocrine VEGF/ KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004;103:3883-9.
    • (2004) Blood , vol.103 , pp. 3883-3889
    • Santos, S.C.1    Dias, S.2
  • 35
  • 36
    • 0024818355 scopus 로고
    • Vascular endothelial growth factor is a secreted angiogenic mitogen
    • Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-9.
    • (1989) Science , vol.246 , pp. 1306-1309
    • Leung, D.W.1    Cachianes, G.2    Kuang, W.J.3    Goeddel, D.V.4    Ferrara, N.5
  • 37
    • 0034923443 scopus 로고    scopus 로고
    • Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia
    • Yetgin S, Yenicesu I, Cetin M, Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42:83-8.
    • (2001) Leuk Lymphoma , vol.42 , pp. 83-88
    • Yetgin, S.1    Yenicesu, I.2    Cetin, M.3    Tuncer, M.4
  • 38
    • 0030576517 scopus 로고    scopus 로고
    • Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
    • Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64.
    • (1996) Cell , vol.86 , pp. 353-364
    • Hanahan, D.1    Folkman, J.2
  • 39
    • 34247177839 scopus 로고    scopus 로고
    • Angiogenesis and antiangiogenic therapy in hematologic malignancies
    • Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol. 2007;62:105-18.
    • (2007) Crit Rev Oncol Hematol , vol.62 , pp. 105-118
    • Dong, X.1    Han, Z.C.2    Yang, R.3
  • 40
    • 0036841072 scopus 로고    scopus 로고
    • Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    • Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95:1923-30.
    • (2002) Cancer , vol.95 , pp. 1923-1930
    • Aguayo, A.1    Kantarjian, H.M.2    Estey, E.H.3    Giles, F.J.4    Verstovsek, S.5    Manshouri, T.6
  • 41
    • 0033485961 scopus 로고    scopus 로고
    • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
    • Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-21.
    • (1999) Blood , vol.94 , pp. 3717-3721
    • Aguayo, A.1    Estey, E.2    Kantarjian, H.3    Mansouri, T.4    Gidel, C.5    Keating, M.6
  • 42
    • 0030933923 scopus 로고    scopus 로고
    • Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
    • Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870-5.
    • (1997) Blood , vol.89 , pp. 1870-1875
    • Fiedler, W.1    Graeven, U.2    Ergün, S.3    Verago, S.4    Kilic, N.5    Stockschläder, M.6
  • 43
    • 0034329298 scopus 로고    scopus 로고
    • In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
    • Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181-7.
    • (2000) Blood , vol.96 , pp. 3181-3187
    • Chen, H.1    Treweeke, A.T.2    West, D.C.3    Till, K.J.4    Cawley, J.C.5    Zuzel, M.6
  • 44
    • 84875893975 scopus 로고    scopus 로고
    • High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes
    • Gianelli U, Fracchiolla NS, Bucciarelli P, Ferla V, Boiocchi L, Savi F, et al. High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes. Am J Clin Pathol. 2013;139:380-7.
    • (2013) Am J Clin Pathol , vol.139 , pp. 380-387
    • Gianelli, U.1    Fracchiolla, N.S.2    Bucciarelli, P.3    Ferla, V.4    Boiocchi, L.5    Savi, F.6
  • 45
    • 84874771894 scopus 로고    scopus 로고
    • Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway
    • Zhang J, Ye J, Ma D, Liu N, Wu H, Yu S, et al. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis. 2013;34:667-77.
    • (2013) Carcinogenesis , vol.34 , pp. 667-677
    • Zhang, J.1    Ye, J.2    Ma, D.3    Liu, N.4    Wu, H.5    Yu, S.6
  • 46
    • 0025717523 scopus 로고
    • Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
    • Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 1991;13:31-6.
    • (1991) Bioessays , vol.13 , pp. 31-36
    • Kerbel, R.S.1
  • 47
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 48
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med. 2006;355:2542-50.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 49
    • 34249721065 scopus 로고    scopus 로고
    • Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity
    • Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia. 2007;21:1310-2.
    • (2007) Leukemia , vol.21 , pp. 1310-1312
    • Zahiragic, L.1    Schliemann, C.2    Bieker, R.3    Thoennissen, N.H.4    Burow, K.5    Kramer, C.6
  • 50
    • 2542547507 scopus 로고    scopus 로고
    • Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
    • Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004;10:3577-85.
    • (2004) Clin Cancer Res , vol.10 , pp. 3577-3585
    • Karp, J.E.1    Gojo, I.2    Pili, R.3    Gocke, C.D.4    Greer, J.5    Guo, C.6
  • 51
    • 84870740661 scopus 로고    scopus 로고
    • Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: A randomized phase 2 trial of the Dutch-Belgian cooperative trial group for hemato-oncology (HOVON) and the swiss group for clinical cancer research (SAKK)
    • Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood. 2012;120:4706-11.
    • (2012) Blood , vol.120 , pp. 4706-4711
    • Ossenkoppele, G.J.1    Stussi, G.2    Maertens, J.3    Van Montfort, K.4    Biemond, B.J.5    Breems, D.6
  • 54
    • 0037099598 scopus 로고    scopus 로고
    • PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
    • Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002;62:4015-22.
    • (2002) Cancer Res , vol.62 , pp. 4015-4022
    • Drevs, J.1    Müller-Driver, R.2    Wittig, C.3    Fuxius, S.4    Esser, N.5    Hugenschmidt, H.6
  • 55
    • 20444473802 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours
    • Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer. 2005;41:1291-9.
    • (2005) Eur J Cancer , Issue.41 , pp. 1291-1299
    • Mross, K.1    Drevs, J.2    Müller, M.3    Medinger, M.4    Marmé, D.5    Hennig, J.6
  • 56
    • 33744482540 scopus 로고    scopus 로고
    • Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
    • Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006;20:952-7.
    • (2006) Leukemia , vol.20 , pp. 952-957
    • Roboz, G.J.1    Giles, F.J.2    List, A.F.3    Cortes, J.E.4    Carlin, R.5    Kowalski, M.6
  • 57
    • 84884813690 scopus 로고    scopus 로고
    • Alliance for clinical trials in oncology. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
    • Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, et al.; Alliance for Clinical Trials in Oncology. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013;31:1311-20.
    • (2013) Invest New Drugs , vol.31 , pp. 1311-1320
    • Gupta, P.1    Mulkey, F.2    Hasserjian, R.P.3    Sanford, B.L.4    Vij, R.5    Hurd, D.D.6
  • 58
    • 20144370978 scopus 로고    scopus 로고
    • AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
    • Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389-400.
    • (2005) Cancer Res , vol.65 , pp. 4389-4400
    • Wedge, S.R.1    Kendrew, J.2    Hennequin, L.F.3    Valentine, P.J.4    Barry, S.T.5    Brave, S.R.6
  • 59
    • 34547681379 scopus 로고    scopus 로고
    • Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
    • Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045-54.
    • (2007) J Clin Oncol , vol.25 , pp. 3045-3054
    • Drevs, J.1    Siegert, P.2    Medinger, M.3    Mross, K.4    Strecker, R.5    Zirrgiebel, U.6
  • 60
    • 74849101514 scopus 로고    scopus 로고
    • An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia
    • Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U, et al. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk Res. 2010;34:196-202.
    • (2010) Leuk Res , vol.34 , pp. 196-202
    • Fiedler, W.1    Mesters, R.2    Heuser, M.3    Ehninger, G.4    Berdel, W.E.5    Zirrgiebel, U.6
  • 61
    • 69249221392 scopus 로고    scopus 로고
    • Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation
    • Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567-71.
    • (2009) Blood , vol.113 , pp. 6567-6571
    • Metzelder, S.1    Wang, Y.2    Wollmer, E.3    Wanzel, M.4    Teichler, S.5    Chaturvedi, A.6
  • 62
    • 9144269029 scopus 로고    scopus 로고
    • FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
    • Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103:267-74.
    • (2004) Blood , vol.103 , pp. 267-274
    • Zheng, R.1    Levis, M.2    Piloto, O.3    Brown, P.4    Baldwin, B.R.5    Gorin, N.C.6
  • 63
    • 56949083913 scopus 로고    scopus 로고
    • Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia
    • Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res. 2009;33:348-50.
    • (2009) Leuk Res , vol.33 , pp. 348-350
    • Safaian, N.N.1    Czibere, A.2    Bruns, I.3    Fenk, R.4    Reinecke, P.5    Dienst, A.6
  • 64
    • 84886534519 scopus 로고    scopus 로고
    • Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: Results from a randomized, placebo-controlled trial
    • Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31:3110-8.
    • (2013) J Clin Oncol , vol.31 , pp. 3110-3118
    • Serve, H.1    Krug, U.2    Wagner, R.3    Sauerland, M.C.4    Heinecke, A.5    Brunnberg, U.6
  • 65
    • 84911405571 scopus 로고    scopus 로고
    • Récher C. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations
    • Epub ahead of print
    • Guenounou S, Delabesse E, Récher C. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. Eur J Haematol. 2014. doi: 10.1111/ejh.12334. [Epub ahead of print]
    • (2014) Eur J Haematol
    • Guenounou, S.1    Delabesse, E.2
  • 66
    • 84904043013 scopus 로고    scopus 로고
    • Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
    • Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, et al. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014;28:1543-5.
    • (2014) Leukemia , vol.28 , pp. 1543-1545
    • Ravandi, F.1    Arana Yi, C.2    Cortes, J.E.3    Levis, M.4    Faderl, S.5    Garcia-Manero, G.6
  • 67
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Desikan, R.3    Ayers, D.4    Roberson, P.5
  • 68
    • 0035880229 scopus 로고    scopus 로고
    • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
    • Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-4.
    • (2001) Blood , vol.98 , pp. 492-494
    • Barlogie, B.1    Desikan, R.2    Eddlemon, P.3    Spencer, T.4    Zeldis, J.5    Munshi, N.6
  • 71
    • 27644591608 scopus 로고    scopus 로고
    • Properties of thalidomide and its analogues: Implications for anticancer therapy
    • Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005, 7:E14-19.
    • (2005) AAPS J , vol.7 , pp. E14-E19
    • Teo, S.K.1
  • 72
    • 0037021257 scopus 로고    scopus 로고
    • Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects
    • Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, et al. Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87:1166-72.
    • (2002) Br J Cancer , vol.87 , pp. 1166-1172
    • Dredge, K.1    Marriott, J.B.2    Macdonald, C.D.3    Man, H.W.4    Chen, R.5    Muller, G.W.6
  • 73
    • 0242298170 scopus 로고    scopus 로고
    • Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    • Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2003;123:436-41.
    • (2003) Br J Haematol , vol.123 , pp. 436-441
    • Thomas, D.A.1    Estey, E.2    Giles, F.J.3    Faderl, S.4    Cortes, J.5    Keating, M.6
  • 74
    • 0036464605 scopus 로고    scopus 로고
    • Efficacy and safety of thalidomide in patients with acute myeloid leukemia
    • Steins MB, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood. 2002;99:834-9.
    • (2002) Blood , vol.99 , pp. 834-839
    • Steins, M.B.1    Padró, T.2    Bieker, R.3    Ruiz, S.4    Kropff, M.5    Kienast, J.6
  • 75
    • 60849098162 scopus 로고    scopus 로고
    • Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
    • Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009;113:1002-5.
    • (2009) Blood , vol.113 , pp. 1002-1005
    • Fehniger, T.A.1    Byrd, J.C.2    Marcucci, G.3    Abboud, C.N.4    Kefauver, C.5    Payton, J.E.6
  • 76
    • 79960687125 scopus 로고    scopus 로고
    • A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
    • Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011;118:523-8.
    • (2011) Blood , vol.118 , pp. 523-528
    • Sekeres, M.A.1    Gundacker, H.2    Lancet, J.3    Advani, A.4    Petersdorf, S.5    Liesveld, J.6
  • 77
    • 42449130564 scopus 로고    scopus 로고
    • Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1
    • Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008;111:3131-6.
    • (2008) Blood , vol.111 , pp. 3131-3136
    • Shin, D.H.1    Chun, Y.S.2    Lee, D.S.3    Huang, L.E.4    Park, J.W.5
  • 78
    • 0642349188 scopus 로고    scopus 로고
    • Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
    • Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003;2:835-43.
    • (2003) Mol Cancer Ther , vol.2 , pp. 835-843
    • Williams, S.1    Pettaway, C.2    Song, R.3    Papandreou, C.4    Logothetis, C.5    McConkey, D.J.6
  • 79
    • 31544433927 scopus 로고    scopus 로고
    • Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
    • Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66:184-91.
    • (2006) Cancer Res , vol.66 , pp. 184-191
    • Roccaro, A.M.1    Hideshima, T.2    Raje, N.3    Kumar, S.4    Ishitsuka, K.5    Yasui, H.6
  • 80
    • 84875693885 scopus 로고    scopus 로고
    • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502
    • Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31:923-9.
    • (2013) J Clin Oncol , vol.31 , pp. 923-929
    • Attar, E.C.1    Johnson, J.L.2    Amrein, P.C.3    Lozanski, G.4    Wadleigh, M.5    DeAngelo, D.J.6
  • 82
    • 0035207952 scopus 로고    scopus 로고
    • Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis
    • Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001;28:565-9.
    • (2001) Semin Oncol , vol.28 , pp. 565-569
    • Munshi, N.C.1    Wilson, C.2
  • 83
    • 0035880256 scopus 로고    scopus 로고
    • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
    • Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428-35.
    • (2001) Blood , vol.98 , pp. 428-435
    • Podar, K.1    Tai, Y.T.2    Davies, F.E.3    Lentzsch, S.4    Sattler, M.5    Hideshima, T.6
  • 84
    • 13544255403 scopus 로고    scopus 로고
    • The pathophysiological role of VEGF in hematological malignancies: Therapeutic implications
    • Podar K, Anderson KC. The pathophysiological role of VEGF in hematological malignancies: Therapeutic implications. Blood. 2005;105:1383-95.
    • (2005) Blood , vol.105 , pp. 1383-1395
    • Podar, K.1    Anderson, K.C.2
  • 85
    • 0035880229 scopus 로고    scopus 로고
    • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
    • Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-4.
    • (2001) Blood , vol.98 , pp. 492-494
    • Barlogie, B.1    Desikan, R.2    Eddlemon, P.3    Spencer, T.4    Zeldis, J.5    Munshi, N.6
  • 86
    • 33644831033 scopus 로고    scopus 로고
    • Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group
    • Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431 6.
    • (2006) J Clin Oncol , vol.24 , Issue.431 , pp. 6
    • Rajkumar, S.V.1    Blood, E.2    Vesole, D.3    Fonseca, R.4    Greipp, P.R.5
  • 87
    • 36349023319 scopus 로고    scopus 로고
    • Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    • Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-32.
    • (2007) N Engl J Med , vol.357 , pp. 2123-2132
    • Dimopoulos, M.1    Spencer, A.2    Attal, M.3    Prince, H.M.4    Harousseau, J.L.5    Dmoszynska, A.6
  • 88
    • 36349010285 scopus 로고    scopus 로고
    • Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    • Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al.; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-42.
    • (2007) N Engl J Med , Issue.357 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3    Wang, M.4    Belch, A.5    Stadtmauer, E.A.6
  • 89
    • 79953300083 scopus 로고    scopus 로고
    • Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma
    • De Luisi A, Ferrucci A, Coluccia AM, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res. 2011;17:1935-46.
    • (2011) Clin Cancer Res , vol.17 , pp. 1935-1946
    • De A, L.1    Ferrucci, A.2    Coluccia, A.M.3
  • 90
    • 79960846565 scopus 로고    scopus 로고
    • Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California cancer consortium trial
    • Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, et al. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma:a California Cancer Consortium trial. Br J Haematol. 2011;154:533-5.
    • (2011) Br J Haematol , vol.154 , pp. 533-535
    • Somlo, G.1    Lashkari, A.2    Bellamy, W.3    Zimmerman, T.M.4    Tuscano, J.M.5    O'Donnell, M.R.6
  • 91
    • 84872068442 scopus 로고    scopus 로고
    • Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
    • White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 2013;119:339-47.
    • (2013) Cancer , vol.119 , pp. 339-347
    • White, D.1    Kassim, A.2    Bhaskar, B.3    Yi, J.4    Wamstad, K.5    Paton, V.E.6
  • 93
    • 33747199312 scopus 로고    scopus 로고
    • Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
    • Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-80.
    • (2006) Blood , vol.108 , pp. 1377-1380
    • Kralovics, R.1    Teo, S.S.2    Li, S.3    Theocharides, A.4    Buser, A.S.5    Tichelli, A.6
  • 94
    • 84890372480 scopus 로고    scopus 로고
    • Somatic mutations of calreticulin in myeloproliferative neoplasms
    • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379-90.
    • (2013) N Engl J Med , vol.369 , pp. 2379-2390
    • Klampfl, T.1    Gisslinger, H.2    Harutyunyan, A.S.3
  • 95
    • 84890328032 scopus 로고    scopus 로고
    • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391-405.
    • (2013) N Engl J Med , vol.369 , pp. 2391-2405
    • Nangalia, J.1    Massie, C.E.2    Baxter, E.J.3
  • 96
    • 0033898269 scopus 로고    scopus 로고
    • Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
    • Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15-19.
    • (2000) Am J Pathol , vol.157 , pp. 15-19
    • Lundberg, L.G.1    Lerner, R.2    Sundelin, P.3    Rogers, R.4    Folkman, J.5    Palmblad, J.6
  • 97
    • 38049049687 scopus 로고    scopus 로고
    • VEGF expression correlates with microvessel density in Philadelphia chromosomenegative chronic myeloproliferative disorders
    • Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, et al. VEGF expression correlates with microvessel density in Philadelphia chromosomenegative chronic myeloproliferative disorders. Am J Clin Pathol. 2007;128:966-73.
    • (2007) Am J Clin Pathol , vol.128 , pp. 966-973
    • Gianelli, U.1    Vener, C.2    Raviele, P.R.3    Savi, F.4    Somalvico, F.5    Calori, R.6
  • 98
    • 67149133738 scopus 로고    scopus 로고
    • The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
    • Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113:5246-9.
    • (2009) Blood , vol.113 , pp. 5246-5249
    • Sozer, S.1    Fiel, M.I.2    Schiano, T.3    Xu, M.4    Mascarenhas, J.5    Hoffman, R.6
  • 99
    • 34249826968 scopus 로고    scopus 로고
    • PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
    • Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007;31:891-7.
    • (2007) Leuk Res , vol.31 , pp. 891-897
    • Giles, F.J.1    List, A.F.2    Carroll, M.3    Cortes, J.E.4    Valickas, J.5    Chen, B.L.6
  • 101
    • 33746989740 scopus 로고    scopus 로고
    • Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: A prospective, randomized, double-blind, multicenter study
    • Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, et al.; Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS). Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica. 2006;91:1027-32.
    • (2006) Haematologica , vol.91 , pp. 1027-1032
    • Abgrall, J.F.1    Guibaud, I.2    Bastie, J.N.3    Flesch, M.4    Rossi, J.F.5    Lacotte-Thierry, L.6
  • 103
    • 70350439432 scopus 로고    scopus 로고
    • Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis
    • Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27:4760-6.
    • (2009) J Clin Oncol , vol.27 , pp. 4760-4766
    • Quintás-Cardama, A.1    Kantarjian, H.M.2    Manshouri, T.3    Thomas, D.4    Cortes, J.5    Ravandi, F.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.